宫颈癌治疗历经百年演进，已经实现从经验医学向循证医学与精准医学，从局部根治向全身精准诊疗的历史性跨越，其各领域的治疗演进历程如下。①手术领域：Wertheim宫颈癌根治术的奠基、Piver分型(按照手术范围将宫颈癌患者手术依次分为Ⅰ~Ⅴ型)的规范及Querleu-Morrow分型(在Piver分型基础上对上述5型子宫切除术进一步细分)的精准化，共同勾勒出宫颈癌外科手术治疗规范化的"三部曲"。②放疗领域：治疗手段从镭疗发展为内外照射联合放疗，直至1999年5项随机对照试验(RCT)确立同步放化疗标准，实现了宫颈癌治疗史上的首次飞跃。③化疗与靶向治疗领域：妇科肿瘤学组(GOG)-169和GOG-179研究奠定了宫颈癌患者的联合化疗基础，GOG-240研究证实贝伐珠单抗可为宫颈癌患者带来总体生存(OS)期获益，抗体药物偶联物(ADC)历经维替索妥尤单抗(TV)等药物的系列开发，推动治疗由"化疗主导"走向"生物标志物驱动"的精准治疗新格局。④免疫治疗领域：以KEYNOTE-158研究实现了宫颈癌患者的后线治疗方案的破冰、KEYNOTE-826研究改写一线治疗标准；CALLA与KEYNOTE-A18研究结果"一阴一阳"(前者为阴性、后者为阳性)，提示精准的人群选择是改善宫颈癌患者治疗疗效的关键。此外，中国学者在宫颈癌微创手术证据辨析、用化疗替代放疗以保护患者生活质量等方向作出了独特贡献。笔者拟基于临床研究证据，从传统手术、放疗、化疗及靶向治疗、免疫治疗与前沿进展等方面，系统梳理宫颈癌治疗的演进历程，聚焦多维度分子分层、治疗性宫颈癌疫苗与个体化联合策略，以期为宫颈癌患者的个体化诊疗与临床实践提供参考，并探讨宫颈癌从"治疗"走向"消除"的筛查-疫苗-治疗协同机制，为其他实体瘤的治疗模式提供范本。

Cervical cancer treatment has undergone over a century of evolution, achieving a historic leap from empirical medicine to evidence-based medicine and precision medicine, and from local radical treatment to systemic precision diagnosis and treatment. The evolutionary process is briefly summarized as follows. ① In the field of surgery, the foundation of the Wertheim radical hysterectomy for cervical cancer, the standardization of the Piver classification (which classifies cervical cancer surgeries into 5 types according to the extent of resection), and the refinement of the Querleu-Morrow classification (which further subdivides the five types of hysterectomy based on the Piver classification) together outline the " trilogy" of standardized surgical treatment for cervical cancer. ② In the field of radiotherapy, treatment modalities evolved from radium therapy to combined external-beam and intracavitary irradiation, until 1999 when five randomized controlled trials (RCTs) established concurrent chemoradiotherapy as the standard, achieving the first leap in the history of cervical cancer treatment. ③ In the field of chemotherapy and targeted therapy, Gynecologic Oncology Group (GOG)-169 and GOG-179 laid the foundation for combination chemotherapy, GOG-240 confirmed that bevacizumab provides overall survival (OS) benefit for patients with cervical cancer, and antibody-drug conjugates(ADC), through the serial development of agents such as tisotumab vedotin (TV), have driven treatment from a " chemotherapy-dominated" approach toward a new paradigm of biomarker-driven precision therapy. ④ In the field of immunotherapy, KEYNOTE-158 achieved a breakthrough in later-line treatment options, and KEYNOTE-826 rewrote the standard of care for first-line treatment; the results of CALLA and KEYNOTE-A18 were one " negative" and one " positive" (the former negative, the latter positive), suggesting that precise patient selection is the key to improving treatment efficacy. In addition, Chinese scholars have made unique contributions in areas such as the critical appraisal of evidence for minimally invasive surgery in cervical cancer and the use of chemotherapy as an alternative to radiotherapy to preserve patients′ quality of life. Based on clinical research evidence, the authors intend to systematically review the evolution of cervical cancer treatment from the aspects of conventional surgery, radiotherapy, chemotherapy and targeted therapy, immunotherapy, and frontier advances, focusing on multidimensional molecular stratification, therapeutic vaccines, and individualized combination strategies, with the aim of providing a reference for individualized diagnosis and treatment and clinical practice of cervical cancer, and exploring the synergistic mechanism of screening-vaccination-treatment in the transition of cervical cancer from " treatment" to " elimination", thereby providing a model for the treatment patterns of other solid tumors.